Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam

Table 4

Determinants of lipodystrophy among HIV-infected patients in Dar es Salaam.

Variables	AOR	95% CI	value
Age (years)
≤30	Ref
31–40	0.18	0.05–0.65	0.009
41–50	0.59	0.30–1.15	0.120
≥51	1.12	0.58–2.19	0.735
Gender
Female	Ref
Male	1.66	1.01–2.72	0.045
HAAT use
HAART naïve	Ref
On HAART	13.3	6.4–27.7	<0.001
Type of HAART used
Nevirapine based	Ref
Efavirenz based	0.98	0.36–2.66	0.962
Stavudine based	3.22	1.17–8.81	0.023
Protease Inhibitor based	1.06	0.08–9.02	1.00
Duration of HAART use
HAART naïve	Ref
24 months	12.8	6.0–27.6	<0.001
25–48 months	13.6	5.7–32.4	<0.001
>48 months	15.3	5.3–43.8	<0.001

AOR: Adjusted Odds Ratio; CI: Confidence Interval; HAART: Highly Active Antiretroviral Therapy.